Skip to main content

Table 1 4H11-28z/fIL-12/EFGRt T cell dose escalation

From: A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer

Cohort

Dose level

Cyclophosphamide dose

4H11-28z/fIL-12/EFGRt T cell dose

Number of patients

-I

−1

None

1 × 105 cells/kg

3-6 patients

I

1

None

3 × 105 cells/kg

3-6 patients

II

1

750 mg/m2

3 × 105 cells/kg

3-6 patients

III

2

750 mg/m2

1 × 106 cells/kg

3-6 patients

IV

3

750 mg/m2

3 × 106 cells/kg

3-6 patients

V

4

750 mg/m2

1 × 107 cells/kg

3-6 patients